Cognition Therapeutics launches expanded access program for zervimesine in DLB

COGNITION THERAPEUTICS INC

Anonymous philanthropic donation from family of DLB patient who was in SHIMMER study funds the program.
Open-label EAP: 100 mg oral zervimesine daily for ~1 year; targets ~30 patients initially across 8 U.S. sites.
First site activated: Banner Sun Health Research Institute; Dr. David Shprecher site investigator; Dr. James Galvin lead investigator.
EAP open to eligible SHIMMER completers and other mild-to-moderate DLB patients meeting criteria.
Company aims to start providing zervimesine this month (June 2025).

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.